Study on the safety and efficacy of creatine phosphate in elderly ACS patients

ZHAO Shao-pan; WANG Hao; ZHU Bing; XIAO Wen-kai; CAO Rui-hua; GAO Peng; WANG Hai-jun; DU Rui-xue; ZHANG Xiu-jin; XIAO Tie-hui; LUO Lei-ming

doi:10.3969/j.issn.1674-4055.2017.04.08

Abstract：Objective To evaluate the clinical efficacy and safety of creatine phosphate sodium in elderly patients with acute coronary syndrome (ACS).Methods A total of 79 cases of elderly patients with ACS (aged ≥65 years) were randomly divided into control group (n=35) and creatine phosphate group (CP group,n=44). Two groups were treated with routine medication, the CP group were added creatine (1g, 2/d) intravenous infusion therapy. Both groups were treated for 4 weeks. Before treatment, after 2 weeks of treatment (2 W) and four weeks of treatment (4 W), hypersensitive C reactive protein(hs-CRP), N terminal B type natriuretic titanium precursor(NT-proBNP), hypersensitive cardiac troponin T (hs-cTnT), cardiac troponin I (cTnI) and creatine phosphate metabolites: serum phosphorus (Sp) and serum creatinine (Scr) were measured.Results There was no significant difference between the two groups before treatment (P>0.05). At 2W and 4W, compared with the control group, the hs-cTnT of CP group was significantly decreased (P<0.05). At 2W, the hs-cTnT and cTnI of CP group decreased significantly (P>0.05). At 4W, the hs-CRP and NT-proBNP of CP group were significantly decreased (P>0.05). Compared with 2W, the hs-cTnT and cTnI of CP group were significantly decreased at 4W (P>0.05).Conclusion The levels of hs-CRP, NT-proBNP, hs-cTnT and cTNI in the elderly patients treated with sodium phosphate for 2 weeks and 4 weeks were significantly higher than those in the conventional treatment group, and the levels of serum phosphorus and serum creatinine were not significantly increased. The creatine phosphate sodium is effective in elderly patients with ACS and is worthy of clinical promotion.